Next Article in Journal
Recombinant Antibodies against Mycolactone
Previous Article in Journal
Intramuscular Ricin Poisoning of Mice Leads to Widespread Damage in the Heart, Spleen, and Bone Marrow
Article Menu
Issue 6 (June) cover image

Export Article

Open AccessArticle

Pharmacokinetics of Human Recombinant Anti-Botulinum Toxin Antibodies in Rats

1
Ology Bioservices Inc., 630 Bancroft Way, Suite D, Berkeley, CA 94710, USA
2
Fiveprime Therapeutics Inc., 111 Oyster Point Blvd, South San Francisco, CA 94080, USA
3
Portola Pharmaceuticals Inc., 270 E Grand Ave, South San Francisco, CA 94080, USA
4
OncoMed Inc., 800 Chesapeake Dr, Redwood City, CA 94063, USA
5
Ology Bioservices Inc., 13200 NW Nano Ct, Alachua, FL 32615, USA
6
Department of Anesthesia and Perioperative Care, University of California, San Francisco, 1001 Potrero Ave, San Francisco, CA 94110, USA
*
Author to whom correspondence should be addressed.
Toxins 2019, 11(6), 345; https://doi.org/10.3390/toxins11060345
Received: 30 April 2019 / Revised: 2 June 2019 / Accepted: 3 June 2019 / Published: 17 June 2019
(This article belongs to the Section Bacterial Toxins)
  |  
PDF [3720 KB, uploaded 25 June 2019]
  |  

Abstract

Botulinum neurotoxins (BoNT) are potential biothreat agents due to their high lethality, potency, and ease of distribution, thus the development of antitoxins is a high priority to the US government. This study examined pre-clinical pharmacokinetic studies in rats of four oligoclonal anti-BoNT mAb-based therapeutics (NTM-1631, NTM-1632, NTM-1633, NTM-1634) for five BoNT serotypes (A, B, E, C, and D). NTM-1631, NTM-1632, and NTM-1633 each consist of three IgG1 mAbs, each with a distinct human or humanized variable region which bind to distinct epitopes on BoNT serotype A, B, or E respectively. NTM-1634 consists of four human immunoglobulin G1 (IgG1) mAbs binding BoNT C/D mosaic toxins. The mechanism of these antitoxins requires that three antibodies simultaneously bind toxin to achieve rapid clearance. Rats (total 378) displayed no adverse clinical signs attributed to antibody treatment from any of the antitoxins. Pharmacokinetic evaluation demonstrated that the individual mAbs are slowly eliminated, exhibiting dose-dependent exposure and long elimination half-lives ranging from 6.5 days to 10 days. There were no consistent differences observed between males and females or among the individual antibodies in each formulation in half-life. Anti-drug antibodies (ADA) were observed, as expected for human antibodies administered to rats. The results presented were used to support the clinical investigation of antibody-based botulism antitoxins. View Full-Text
Keywords: botulinum neurotoxin; pharmacokinetics; recombinant antibody; rat; oligoclonal antibody; anti-botulinum neurotoxin antibody botulinum neurotoxin; pharmacokinetics; recombinant antibody; rat; oligoclonal antibody; anti-botulinum neurotoxin antibody
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material

SciFeed

Share & Cite This Article

MDPI and ACS Style

Espinoza, Y.; Wong, D.; Ahene, A.; Der, K.; Martinez, Z.; Pham, J.; Cobb, R.R.; Farr-Jones, S.; Marks, J.D.; Tomic, M.T. Pharmacokinetics of Human Recombinant Anti-Botulinum Toxin Antibodies in Rats. Toxins 2019, 11, 345.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Toxins EISSN 2072-6651 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top